تداخلات بروبينيسيد وكولشيسين

Antigout: colchicine ↑ colchicine The coadministration of REYATAZ with colchicine in patients with renal or hepatic impairment is not recommended. (نشرة أتازانافير، التداخلات الدوائية)

Co-administration with probenecid inhibits the renal excretion of ertapenem and is therefore not recommended. (نشرة إرتابينيم، التداخلات الدوائية)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (نشرة بروبينيسيد وكولشيسين، التحذيرات)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (نشرة بروبينيسيد وكولشيسين، التحذيرات)

Anti-gout: colchicine ↑ colchicine GENVOYA is not recommended to be coadministered with colchicine to patients with renal or hepatic impairment. (نشرة إلفيتيغرافير وكوبيسيستات وإمتريسيتابين وتينوفوفير، التداخلات الدوائية)

Co-administration with probenecid is not recommended. (نشرة أموكسيسيلين وكلافولانات، التداخلات الدوائية)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (نشرة بروبينيسيد وكولشيسين، التحذيرات)

Co-administration with colchicine, fesoterodine and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment. (نشرة إيتراكونازول، تحذير مؤطر)

Therefore, it is not recommended that probenecid be given concomitantly with PRIMAXIN. (نشرة إيميبينيم وسيلاستاتين، التداخلات الدوائية)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (نشرة بروبينيسيد وكولشيسين، التحذيرات)

Avoid coadministration with probenecid or nonsteroidal anti-inflammatory drugs. (نشرة برالاتريكسات، التداخلات الدوائية)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (نشرة بروبينيسيد وكولشيسين، التحذيرات)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (نشرة بروبينيسيد وكولشيسين، التحذيرات)

Thus, probenecid should not be administered concurrently with bumetanide. (نشرة بوميتانيد، التداخلات الدوائية)

Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (نشرة بيبراسيلين وتازوباكتام، التداخلات الدوائية)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (نشرة بروبينيسيد وكولشيسين، التحذيرات)

Alpha 1-adrenoreceptor antagonist: alfuzosin Anti-gout: colchicine, in patients with renal and/or hepatic impairment Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Cardiac Disorders: dronedarone, ivabradine, ranolazine Ergot derivatives, e.g. dihydroergotamine, ergotamine, methylergonovine Herbal product: St. (نشرة دارونافير، موانع الاستعمال)

Alpha 1-adrenoreceptor antagonist: alfuzosin Anticonvulsants: carbamazepine, phenobarbital, phenytoin Anti-gout: colchicine, in patients with renal and/or hepatic impairment Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Cardiac Disorders: dronedarone, ivabradine, ranolazine Ergot derivatives, e.g. dihydroergotamine, ergotamine, methylergonovine… (نشرة دارونافير وكوبيسيستات، موانع الاستعمال)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (نشرة بروبينيسيد وكولشيسين، التحذيرات)

Effect of Other Drugs on FERRIPROX UDP-Glucuronosyltransferases (UGT) Avoid use of UGT1A6 inhibitors (e.g., diclofenac, probenecid, or silymarin (milk thistle)) with FERRIPROX [ see Dosage and Administration ( 2.2 ) , Adverse Reactions ( 6.1 ), Clinical Pharmacology ( 12.3 ) ] . (نشرة ديفيريبرون، التداخلات الدوائية)

…Adrenoreceptor Antagonist: alfuzosin ○ Antianginal: ranolazine ○ Antiarrhythmics: amiodarone, dronedarone, flecainide, propafenone, quinidine ○ Antifungal: voriconazole ○ Anti-gout: colchicine ○ Antipsychotics: lurasidone, pimozide ○ Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine ○ GI Motility Agent: cisapride ○ HMG-CoA Reductase Inhibitors:… (نشرة ريتونافير، موانع الاستعمال)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (نشرة بروبينيسيد وكولشيسين، التحذيرات)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (نشرة بروبينيسيد وكولشيسين، التحذيرات)

TO REDUCE POSSIBLE NEPHROTOXICITY, INTRAVENOUS PREHYDRATION WITH NORMAL SALINE AND ADMINISTRATION OF PROBENECID MUST BE USED WITH EACH CIDOFOVIR INFUSION. (نشرة سيدوفوفير، تحذير مؤطر)

Co-administration of probenecid with Cefazolin for Injection is not recommended. (نشرة سيفازولين، التداخلات الدوائية)

Co-administration of probenecid with cephalexin for oral suspension is not recommended. (نشرة سيفالكسين، التداخلات الدوائية)

Administration of cefotaxime in excess of 6 grams/day should be avoided in patients receiving probenecid (see CLINICAL PHARMACOLOGY, Drug Interactions ). (نشرة سيفوتاكسيم، التداخلات الدوائية)

Coadministration with probenecid increases systemic exposure to cefuroxime axetil and is therefore not recommended. (نشرة سيفوروكسيم، التداخلات الدوائية)

Colchicine in renal or hepatic impairment ( 4.4 ) (نشرة كلاريثرومايسين، موانع الاستعمال)

Therefore, the combination of ketoprofen and probenecid is not recommended. (نشرة كيتوبروفين، التحذيرات والاحتياطات)

The concomitant use of ketorolac tromethamine and probenecid is contraindicated. (نشرة كيتورولاك، موانع الاستعمال)

…contraindicated with ketoconazole tablets: methadone, disopyramide, dronedarone, ergot alkaloids such as dihydroergotamine, ergometrine, ergotamine, methylergometrine, irinotecan, lurasidone, oral midazolam, alprazolam, triazolam, felodipine, nisoldipine, ranolazine, tolvaptan, eplerenone, lovastatin, simvastatin and colchicine (see PRECAUTIONS: Drug Interactions ). (نشرة كيتوكونازول، موانع الاستعمال)

Alpha 1- Adrenoreceptor Antagonist: alfuzosin Antianginal: ranolazine Antiarrhythmic: dronedarone Anti-gout: colchicine Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine GI Motility Agent: cisapride Hepatitis C direct acting antiviral: elbasvir/grazoprevir HMG-CoA Reductase Inhibitors: lovastatin, simvastatin… (نشرة لوبينافير وريتونافير، موانع الاستعمال)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (نشرة بروبينيسيد وكولشيسين، التحذيرات)

Co-administration of Meropenem for injection with probenecid inhibits renal excretion of meropenem and is therefore not recommended ( 7.1 ) (نشرة ميروبينيم، التداخلات الدوائية)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (نشرة بروبينيسيد وكولشيسين، التحذيرات)

…Interactions (7.3) ] : • Alpha 1-adrenoreceptor antagonist: alfuzosin • Antianginal: ranolazine • Antiarrhythmic: amiodarone, dronedarone, flecainide, propafenone, quinidine • Anti-gout: colchicine (in patients with renal and/or hepatic impairment [see Table 2 , Drug Interactions (7.3)] ) • Antipsychotics: lurasidone, pimozide • Benign prostatic hyperplasia agents:… (نشرة نيرماتريلفير وريتونافير، موانع الاستعمال)

Cases of myopathy/rhabdomyolysis have been reported with atorvastatin co-administered with lipid modifying doses (>1 gram/day) of niacin, fibrates, colchicine, and ledipasvir plus sofosbuvir [see Adverse Reactions (6.1) ] . (نشرة أتورفاستاتين، التحذيرات والاحتياطات)

These include colchicine toxicity with colchicine; rhabdomyolysis with simvastatin, lovastatin, and atorvastatin; and hypotension with calcium channel blockers metabolized by CYP3A4 (for example, verapamil, amlodipine, diltiazem) (see PRECAUTIONS, Drug Interactions ). (نشرة إريثرومايسين، التحذيرات)

Until further data are developed regarding drug interactions when digoxin, colchicine or phenytoin are used with azithromycin careful monitoring of patients is advised. (نشرة أزيثرومايسين، التداخلات الدوائية)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

Drug Interactions Coadministration of probenecid with intravenous acyclovir has been shown to increase the mean acyclovir half-life and the area under the concentration-time curve. (نشرة أسيكلوفير، التداخلات الدوائية)

In order to prevent gout flares when treatment with allopurinol tablets is initiated, concurrent prophylactic treatment with colchicine or an anti-inflammatory agent is recommended [ see Dosage and Administration (2.2) ]. (نشرة ألوبيورينول، التحذيرات والاحتياطات)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

Cases of myopathy/rhabdomyolysis have been reported with atorvastatin co-administered with lipid modifying doses (> 1 gram/day) of niacin, fibrates, colchicine, and ledipasvir plus sofosbuvir [see Adverse Reactions (6.1) ] . (نشرة أملوديبين وأتورفاستاتين، التحذيرات والاحتياطات)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

Probenecid Clinical Impact: When indomethacin is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased. (نشرة إندوميثاسين، التداخلات الدوائية)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

In patients on probenecid and colchicine who require a mild analgesic agent the use of acetaminophen rather than small doses of salicylates would be preferred. (نشرة بروبينيسيد وكولشيسين، التحذيرات)

Lipid modifying doses (≥1 gram/day) of niacin, fibrates, colchicine, and grapefruit juice may also increase the risk of myopathy and rhabdomyolysis [see Drug Interactions (7.1) ] . (نشرة إيزيتيميب وسيمفاستاتين، التحذيرات والاحتياطات)

In patients on probenecid and colchicine who require a mild analgesic agent the use of acetaminophen rather than small doses of salicylates would be preferred. (نشرة بروبينيسيد وكولشيسين، التحذيرات)

In patients on probenecid and colchicine who require a mild analgesic agent the use of acetaminophen rather than small doses of salicylates would be preferred. (نشرة بروبينيسيد وكولشيسين، التحذيرات)

In patients on probenecid and colchicine who require a mild analgesic agent the use of acetaminophen rather than small doses of salicylates would be preferred. (نشرة بروبينيسيد وكولشيسين، التحذيرات)

In patients taking strong Organic Anion Transporter 3 (OAT3) inhibitors (e.g., probenecid) the recommended dosage should be reduced. (نشرة باريسيتينيب، التداخلات الدوائية)

The following drugs when used concomitantly with pravastatin sodium may also increase the risk of myopathy and rhabdomyolysis: niacin, fibrates, and colchicine [see Drug Interactions ( 7 )]. (نشرة برافاستاتين، التحذيرات والاحتياطات)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (نشرة بروموكريبتين، التداخلات الدوائية)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

In patients on probenecid and colchicine who require a mild analgesic agent the use of acetaminophen rather than small doses of salicylates would be preferred. (نشرة بروبينيسيد وكولشيسين، التحذيرات)

In patients on probenecid and colchicine who require a mild analgesic agent the use of acetaminophen rather than small doses of salicylates would be preferred. (نشرة بروبينيسيد وكولشيسين، التحذيرات)

In patients on probenecid and colchicine who require a mild analgesic agent the use of acetaminophen rather than small doses of salicylates would be preferred. (نشرة بروبينيسيد وكولشيسين، التحذيرات)

The following drugs when used concomitantly with LIVALO may also increase the risk of myopathy and rhabdomyolysis: lipid-modifying dosages of niacin (>1grams/day), fibrates, and colchicine [see Drug Interactions (7) ]. (نشرة بيتافاستاتين، التحذيرات والاحتياطات)

Probenecid may prolong or enhance the action of oral sulfonylureas and thereby increase the risk of hypoglycemia. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

In patients on probenecid and colchicine who require a mild analgesic agent the use of acetaminophen rather than small doses of salicylates would be preferred. (نشرة بروبينيسيد وكولشيسين، التحذيرات)

Organic Anion Drugs Coadministration of organic anion drugs (e.g., probenecid) that undergo significant renal tubular secretion have the potential to reduce secretion of torsemide into the proximal tubule and thereby decreases the diuretic activity of torsemide. (نشرة توراسيميد، التداخلات الدوائية)

(G) Colchicine Myopathy, including rhabdomyolysis, has been reported with chronic administration of colchicine at therapeutic doses. (نشرة جيمفيبروزيل، التداخلات الدوائية)

Consider whether the benefit of using colchicine concomitantly with fenofibric acid delayed-release capsules outweighs the increased risk of myopathy [see Drug Interactions (7) ] . (نشرة حمض الفينوفيبريك، التحذيرات والاحتياطات)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

Niacin, fibrates, and colchicine may also increase the risk of myopathy and rhabdomyolysis [see Drug Interactions ( 7.1) ]. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

Concomitant use with probenecid and cotrimoxazole increases the concentration of rifampin which may increase the risk of rifampin toxicities. (نشرة ريفامبيسين، التداخلات الدوائية)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

Probenecid given concomitantly with sulindac had only a slight effect on plasma sulfide levels, while plasma levels of sulindac and sulfone were increased. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

Probenecid Clinical Impact: Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly. (نشرة سوماتريبتان ونابروكسين، التداخلات الدوائية)

Decrease ciprofloxacin absorption, resulting in lower serum and urine levels Probenecid Use with caution (interferes with renal tubular secretion of ciprofloxacin and increases ciprofloxacin serum levels) Potentiation of ciprofloxacin toxicity may occur. (نشرة سيبروفلوكساسين، التداخلات الدوائية)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

…Immunosuppressives Other Drugs ciprofloxacin melphalan amphotericin B azapropazon cimetidine tacrolimus fibric acid derivatives (e.g., bezafibrate, fenofibrate) gentamicin ketoconazole colchicine ranitidine methotrexate tobramycin diclofenac trimethoprim with sulfamethoxazole naproxen vancomycin sulindac During the concomitant use of a drug that may exhibit additive… (نشرة سيكلوسبورين، التداخلات الدوائية)

Lipid modifying doses (≥1 gram/day) of niacin, fibrates, colchicine, and grapefruit juice may also increase the risk of myopathy and rhabdomyolysis [see Drug Interactions (7.1) ] . (نشرة سيمفاستاتين، التحذيرات والاحتياطات)

Probenecid ↑Ganciclovir Ganciclovir for Injection dose may need to be reduced. (نشرة غانسيكلوفير، التداخلات الدوائية)

Probenecid may prolong or enhance the action of oral sulfonylureas and thereby increase the risk of hypoglycemia. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

Probenecid may prolong or enhance the action of oral sulfonylureas and thereby increase the risk of hypoglycemia. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

Probenecid may prolong or enhance the action of oral sulfonylureas and thereby increase the risk of hypoglycemia. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

Probenecid may prolong or enhance the action of oral sulfonylureas and thereby increase the risk of hypoglycemia. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

Probenecid may prolong or enhance the action of oral sulfonylureas and thereby increase the risk of hypoglycemia. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

Didanosine ↔ Ganciclovir ↑ Didanosine Patients should be closely monitored for didanosine toxicity (e.g., pancreatitis) Probenecid ↑ Ganciclovir Valganciclovir hydrochloride dose may need to be reduced. (نشرة فالغانسيكلوفير، التداخلات الدوائية)

Probenecid: May increase penciclovir levels. (نشرة فامسيكلوفير، التداخلات الدوائية)

When used concomitantly with fluvastatin sodium extended-release tablets, lipid modifying doses (≥ 1 g/day) of niacin, fibrates, and colchicine may also increase the risk of myopathy and rhabdomyolysis [see Drug Interactions ( 7.1 )] . (نشرة فلوفاستاتين، التحذيرات والاحتياطات)

Fosamprenavir calcium/ritonavir and coadministration of colchicine: Treatment of gout flares: 0.6 mg (1 tablet) x 1 dose, followed by 0.3 mg (half tablet) 1 hour later. (نشرة فوسامبرينافير، التداخلات الدوائية)

In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (نشرة فيبوكسوستات، التحذيرات والاحتياطات)

Consider whether the benefit of using colchicine concomitantly with fenofibrate outweighs the increased risk of myopathy [see Drug Interactions (7) ]. (نشرة فينوفيبرات، التحذيرات والاحتياطات)

Probenecid : May inhibit renal excretion of metabolites of PHEBURANE including phenylacetate and phenylacetylglutamine; monitor for potential neurotoxicity. (نشرة فينيل بوتيرات الصوديوم، التداخلات الدوائية)

Monitor patients for increased toxicity when MRP2 inhibitors (e.g., abacavir, adefovir, cidofovir, furosemide, lamivudine, nevirapine, ritonavir, probenecid, saquinavir, and tenofovir) are co-administered with COMETRIQ [see Clinical Pharmacology ( 12.3 )] . (نشرة كابوزانتينيب، التداخلات الدوائية)

In addition, ketamine and thiopental anesthesia were significantly prolonged in rats receiving probenecid. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

Colchicine: Cases of myopathy, including rhabdomyolysis, have been reported with lovastatin coadministered with colchicine, and caution should be exercised when prescribing lovastatin with colchicine (see PRECAUTIONS , Drug Interactions ). (نشرة لوفاستاتين، التحذيرات)

Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates. (نشرة لوميتابيد، التداخلات الدوائية)

However, these changes do not warrant dosage adjustment for Levofloxacin in 5% Dextrose Injection when probenecid or cimetidine is co-administered. (نشرة ليفوفلوكساسين، التداخلات الدوائية)

Renal clearance of ucb L057 in the presence of probenecid decreased 60%, probably related to competitive inhibition of tubular secretion of ucb L057. (نشرة ليفيتيراسيتام، التداخلات الدوائية)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

Probenecid increases plasma concentrations of methotrexate in both animals and humans. (نشرة بروبينيسيد وكولشيسين، التحذيرات)

Probenecid Clinical Impact: Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly. (نشرة نابروكسين، التداخلات الدوائية)

DRUG INTERACTIONS When probenecid is used to elevate plasma concentrations of penicillin, or other beta-lactams, or when such drugs are given to patients taking probenecid therapeutically, high plasma concentrations of the other drug may increase the incidence of adverse reactions associated with that drug. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

In patients on probenecid and colchicine who require a mild analgesic agent the use of acetaminophen rather than small doses of salicylates would be preferred. (نشرة بروبينيسيد وكولشيسين، التحذيرات)

Falsely high readings for theophylline have been reported in an in vitro study, using the Schack and Waxler technique, when therapeutic concentrations of theophylline and probenecid were added to human plasma. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

Falsely high readings for theophylline have been reported in an in vitro study, using the Schack and Waxler technique, when therapeutic concentrations of theophylline and probenecid were added to human plasma. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

These include probenecid, cholestyramine, and some antibiotics (e.g., erythromycin, rifampicin, ampicillin, and chloramphenicol). (نشرة إنتاكابون، الاحتياطات)

Probenecid The concomitant use of probenecid with certain other quinolones has been reported to affect renal tubular secretion. (نشرة أوفلوكساسين، التداخلات الدوائية)

…hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however), and quinidine; and (6) analgesics, antipyretics and anti-inflammatories–propoxyphene, aspirin, indomethacin,… (نشرة برازوسين، التداخلات الدوائية)

Falsely high readings for theophylline have been reported in an in vitro study, using the Schack and Waxler technique, when therapeutic concentrations of theophylline and probenecid were added to human plasma. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

The uricosuric action of probenecid is also antagonized by pyrazinamide. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

Falsely high readings for theophylline have been reported in an in vitro study, using the Schack and Waxler technique, when therapeutic concentrations of theophylline and probenecid were added to human plasma. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

Probenecid Probenecid is a blocker of renal tubular secretion. (نشرة غابابنتين، التداخلات الدوائية)

Probenecid : May affect renal excretion of metabolites of glycerol phenylbutyrate, including phenylacetylglutamine (PAGN) and PAA. (نشرة غليسرول فينيل بوتيرات، التداخلات الدوائية)

Probenecid is known to inhibit the renal transport of many organic compounds, including aminohippuric acid, and may affect renal excretion of phenylacetylglutamine and hippurate. (نشرة فينيل أسيتات الصوديوم وبنزوات الصوديوم، التداخلات الدوائية)

These include probenecid, cholestyramine, and some antibiotics (e.g., erythromycin, rifampicin, ampicillin and chloramphenicol). (نشرة كاربيدوبا وليفودوبا وإنتاكابون، التداخلات الدوائية)

These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin. (نشرة بروبينيسيد وكولشيسين، التداخلات الدوائية)

Uricosuric Drugs Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin. (نشرة نيتروفورانتوين، التداخلات الدوائية)

Probenecid does not affect renal tubular transport of gentamicin. (نشرة جنتاميسين، التداخلات الدوائية)

Examples Acyclovir, ganciclovir, probenecid, valacyclovir, valganciclovir Combination Oral Contraceptives Clinical Impact Concomitant use with mycophenolate mofetil decreased the systemic exposure to levonorgestrel, but did not affect the systemic exposure to ethinylestradiol [see Clinical Pharmacology ( 12.3 )], which may result in reduced combination oral contraceptive… (نشرة ميكوفينولات، التداخلات الدوائية)